Sort
53,477 grants matching “addiction”
Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults
$2,498,125Joshua D Lee · New York University School Of Medicine · U01 · FY2024 · DA
UNIVERSITY OF TEXAS SPORE IN LUNG CANCER
$2,497,516University Of Texas Sw Med Ctr/Dallas · P50 · FY2001 · CA
TRANSDISCIPLINARY TOBACCO USE RESEARCH CENTER
$2,495,036University Of Southern California · P50 · FY2000 · CA
Treatment for Complex Patients: Continuing and Extended Care
$2,494,181Joseph R Guydish · University Of California, San Francisco · P50 · FY2014 · DA
NIDA CENTER FOR GENETICS STUDIES
$2,489,498Jay Tischfield · Rutgers, The State Univ Of N.J. · N01 · FY2012 · DA
NIDA CENTER FOR GENETICS STUDIES
$2,489,496Jay Tischfield · Rutgers, The State Univ Of N.J. · N01 · FY2013 · DA
Neurobiology of Addiction
$2,488,336George Koob · National Institute On Drug Abuse · ZIA · FY2021 · DA
SPORE in Lung Cancer
$2,487,605University Of Texas Sw Med Ctr/Dallas · P50 · FY2004 · CA
Multiphoton Imaging of Thoughts of Food During Natural and Induced Hunger States
$2,485,888Mark L Andermann · Beth Israel Deaconess Medical Center · DP2 · FY2014 · DK
NIDA Clinical Trials Network: Greater New York Node
$2,483,943John P Rotrosen · New York University School Of Medicine · UG1 · FY2017 · DA
Development of a Soluble Epoxide Hydrolase Inhibitor to Spare or Replace Opioid Analgesics
$2,481,856Irene Cortes-Puch · Eicosis, Llc · UH3 · FY2025 · DA
Tailored Retention and Engagement for Equitable Treatment of OUD and Pain (TREETOP)
$2,480,623Jessica S Merlin · University Of Pittsburgh At Pittsburgh · RM1 · FY2024 · DA
Structural basis for the functions of dopamine receptors, neurotransmitter transporters, and sigma 1 receptor
$2,478,864Lei Shi · National Institute On Drug Abuse · ZIA · FY2023 · DA
Combination Therapies to Defeat Melanoma Resistance
$2,478,520Antoni Ribas · University Of California Los Angeles · P01 · FY2024 · CA
1/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium
$2,478,085Xiawei Ou · Arkansas Children'S Hospital Res Inst · U01 · FY2025 · DA
Testing the Effects of Contingency Management and Behavioral Economics on Buprenorphine-Naloxone Treatment Adherence Using a Sequential Multiple Assignment Randomized Trial (SMART) Design
$2,477,571Karen J Derefinko · University Of Tennessee Health Sci Ctr · R33 · FY2021 · AT
HEAL Clinical Coordinating Resource Center for the Pain Management Effectiveness Research Network
$2,475,031Daniel K Benjamin · Duke University · U24 · FY2023 · TR
Molecular Analysis of Functional Neural Circuits
$2,475,000Leon Reijmers · Tufts University Boston · DP2 · FY2009 · OD
A novel geometric paradigm for nonlinear modeling and control of neural dynamics
$2,475,000Maryam Shanechi · University Of Southern California · DP2 · FY2020 · MH
Hypothalamic neuronal circuits controlling survival behaviors
$2,471,993Yeka Aponte · National Institute On Drug Abuse · ZIA · FY2023 · DA
Neuroimaging and neuromodulation of preclinical models of substance use disorders
$2,468,513Yihong Yang · National Institute On Drug Abuse · ZIA · FY2023 · DA
Implementing genomic medicine through pragmatic trials in diverse and underserved populations across Indiana.
$2,468,344Todd C. Skaar · Indiana University Indianapolis · U01 · FY2020 · HG
Using mouse pain scales to discover unusual pain sensitivity and new pain targets
$2,467,500Ishmail John Abdus-Saboor · Columbia Univ New York Morningside · DP2 · FY2022 · NS
Vaccines for prescription opioid and heroin abuse
$2,467,399Paul Pentel · Hennepin Healthcare Research Institute · U01 · FY2015 · DA
Discovery and validation of novel targets for pharmacotherapy of alcoholism
$2,465,593Markus Heilig · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2010 · AA